產品名稱:Rabbit Anti-VEGF-C antibody
Rabbit Anti-VEGF-C
別名:Vascuoar endothelial growth factor-C; AW228853; Flt4 ligand; Flt4-L; VEGF2; VEGFC; VRP; VEGFC_HUMAN.
來源:Rabbit
克隆類型:Polyclonal
濃度:1mg/ml
亞型:IgG
應用: WB=1:1000-1:2000,Elisa=1:1000-1:2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500
反應:Human,Mouse (predicted: Rat,Pig,Horse)
理論分子量:46kDa
免疫原:KLH conjugated synthetic peptide derived from human VEGF-C
保存:-20℃
保質期:1年
單克隆抗體
產品名稱:Anti-VEGF-C antibody
Mouse Anti-VEGF-C
別名:Vascuoar endothelial growth factor-C; AW228853; Flt4 ligand; Flt4-L; VEGF2; VEGFC; VRP; VEGFC_HUMAN.
來源:Mouse
克隆類型:Monoclonal
濃度:1mg/ml
亞型:IgG
應用: WB=1:1000-1:2000,Elisa=1:1000-1:2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500
反應: Human
理論分子量:46kDa
免疫原:KLH conjugated synthetic peptide derived from human VEGF-C
保存:-20℃
保質期:1年
Vascular endothelial growth factors (VEGFs), also known as vasculotropins, are a family of closely related growth factors having a conserved pattern of eight cysteine residues and sharing common VEGF receptors. VEGFs stimulate the proliferation of endothelial cells, induce angiogenesis, promote cell migration, increase vascular permeability, and inhibit apoptosis. The mitogenic activity of VEGFs appears to be mediated by specific VEGF receptors. The target cell specificity of VEGF is restricted to vascular endothelial cells. Vascular Endothelial Growth Factor C (VEGFC) is a member of the VEGF subfamily of PDGF-related growth factors. It is the ligand for Flt4 (VEGFR3) and KDR (VEGFR2). VEGFC binds Flt4 and induces tyrosine autophosphorylation of VEGFR3 and VEGFR2. VEGFC also stimulates the migration of bovine capillary endothelial cells in collagen gel. It is a specific growth factor for the lymphatic vascular system and mediates lymphangiogenesis. VEGFC is abundantly expressed in heart and skeletal muscle. Other tissues such as lung and kidney also express VEGFC.
產品名稱:Rabbit Anti-VEGF-C antibody
Rabbit Anti-VEGF-C
別名:Vascuoar endothelial growth factor-C; AW228853; Flt4 ligand; Flt4-L; VEGF2; VEGFC; VRP; VEGFC_HUMAN.
來源:Rabbit
克隆類型:Polyclonal
濃度:1mg/ml
亞型:IgG
應用: WB=1:1000-1:2000,Elisa=1:1000-1:2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500
反應:Human,Mouse (predicted: Rat,Pig,Horse)
理論分子量:46kDa
免疫原:KLH conjugated synthetic peptide derived from human VEGF-C
保存:-20℃
保質期:1年
單克隆抗體
產品名稱:Anti-VEGF-C antibody
Mouse Anti-VEGF-C
別名:Vascuoar endothelial growth factor-C; AW228853; Flt4 ligand; Flt4-L; VEGF2; VEGFC; VRP; VEGFC_HUMAN.
來源:Mouse
克隆類型:Monoclonal
濃度:1mg/ml
亞型:IgG
應用: WB=1:1000-1:2000,Elisa=1:1000-1:2000,IHC-P=1:100-500,IHC-F=1:100-500,ICC/IF=1:100-500,IF=1:100-500
反應: Human
理論分子量:46kDa
免疫原:KLH conjugated synthetic peptide derived from human VEGF-C
保存:-20℃
保質期:1年
Vascular endothelial growth factors (VEGFs), also known as vasculotropins, are a family of closely related growth factors having a conserved pattern of eight cysteine residues and sharing common VEGF receptors. VEGFs stimulate the proliferation of endothelial cells, induce angiogenesis, promote cell migration, increase vascular permeability, and inhibit apoptosis. The mitogenic activity of VEGFs appears to be mediated by specific VEGF receptors. The target cell specificity of VEGF is restricted to vascular endothelial cells. Vascular Endothelial Growth Factor C (VEGFC) is a member of the VEGF subfamily of PDGF-related growth factors. It is the ligand for Flt4 (VEGFR3) and KDR (VEGFR2). VEGFC binds Flt4 and induces tyrosine autophosphorylation of VEGFR3 and VEGFR2. VEGFC also stimulates the migration of bovine capillary endothelial cells in collagen gel. It is a specific growth factor for the lymphatic vascular system and mediates lymphangiogenesis. VEGFC is abundantly expressed in heart and skeletal muscle. Other tissues such as lung and kidney also express VEGFC.
免責聲明
- 凡本網注明“來源:化工儀器網”的所有作品,均為浙江興旺寶明通網絡有限公司-化工儀器網合法擁有版權或有權使用的作品,未經本網授權不得轉載、摘編或利用其它方式使用上述作品。已經本網授權使用作品的,應在授權范圍內使用,并注明“來源:化工儀器網”。違反上述聲明者,本網將追究其相關法律責任。
- 本網轉載并注明自其他來源(非化工儀器網)的作品,目的在于傳遞更多信息,并不代表本網贊同其觀點和對其真實性負責,不承擔此類作品侵權行為的直接責任及連帶責任。其他媒體、網站或個人從本網轉載時,必須保留本網注明的作品第一來源,并自負版權等法律責任。
- 如涉及作品內容、版權等問題,請在作品發表之日起一周內與本網聯系,否則視為放棄相關權利。